Wave Life Sciences Ltd.
General ticker "WVE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.4B (TTM average)
Wave Life Sciences Ltd. follows the US Stock Market performance with the rate: 34.7%.
Estimated limits based on current volatility of 1.4%: low 7.13$, high 7.51$
Factors to consider:
- Total employees count: 288 as of 2024
- Top business risk factors: Insufficient funding, Economic downturns and volatility, Labor/talent shortage/retention, Pandemic risks, Cybersecurity threats
- Current price 14.9% below estimated low
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.80$, 21.15$]
- 2026-12-31 to 2027-12-31 estimated range: [6.46$, 16.36$]
Financial Metrics affecting the WVE estimates:
- Negative: with PPE of -14.0 at the end of fiscal year the price was high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.49 <= 0.07
- Positive: Inventory ratio change, % of -13.13 <= -0.75
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of -0.02 > -0.65
- Negative: negative Industry operating cash flow (median)
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Shareholder equity ratio, % of 82.42 > 64.25
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term WVE quotes
Long-term WVE plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $113.31MM | $108.30MM | $42.73MM |
| Operating Expenses | $181.30MM | $218.71MM | $258.11MM |
| Operating Income | $-68.00MM | $-110.40MM | $-215.38MM |
| Non-Operating Income | $9.81MM | $13.39MM | $11.01MM |
| R&D Expense | $130.01MM | $159.68MM | $182.78MM |
| Income(Loss) | $-58.19MM | $-97.01MM | $-204.38MM |
| Taxes | $-0.68MM | $0.00MM | $0.00MM |
| Profit(Loss)* | $-57.51MM | $-97.01MM | $-204.38MM |
| Stockholders Equity | $39.63MM | $209.51MM | $526.23MM |
| Assets | $274.95MM | $352.21MM | $638.50MM |
| Operating Cash Flow | $-19.43MM | $-151.03MM | $-187.49MM |
| Capital expenditure | $1.11MM | $0.94MM | $0.72MM |
| Investing Cash Flow | $-1.11MM | $-0.94MM | $-0.72MM |
| Financing Cash Flow | $132.53MM | $253.89MM | $488.24MM |
| Earnings Per Share** | $-0.54 | $-0.70 | $-1.21 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.